NCT01624441: Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Completed | 1 | 40 | US | Dinaciclib, CDK Inhibitor SCH 727965, MK-7965, SCH 727965, Epirubicin Hydrochloride, Ellence, IMI-28, Pharmorubicin PFS, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma | 09/13 | 09/13 | | |
